News | April 15, 2009

Zecotek Photonics Earns Frost & Sullivan Enabling Technology Award

April 15, 2009 - Based on its recent analysis of the U.S. PET and PET/CT markets, Frost & Sullivan awarded Zecotek Photonics Inc. with its 2009 North American Frost & Sullivan Award for Enabling Technology.

According to Frost & Sullivan, Zecotek's outstanding research and development has brought forth innovative scintillation crystal and solid-state photo detector technologies that will help deliver cutting-edge oncology, neurology and cardiology imaging equipment.

"Zecotek is favorably positioned as a global competitor, having been issued or allowed patents for its lutetium fine silicate (LFS) scintillation crystals in many countries and a series of pending and granted patents for its novel solid-state photomultiplier and Depth of Interaction design considerations," said Travis Chong, an industry analyst for Frost & Sullivan. "The company is integrating all these components into what it has dubbed the 'Plug to Socket', a very compact detector module element that captures high resolution images, is easy to install, and requires very low servicing."

Zecotek has emerged as a leader in developing affordable, sophisticated photodetector and solid-state technologies for PET/CT and other medical applications. The company first set the standard with its micro-pixel avalanche photo diode (MAPD)-1 concept, whose design and performance characteristics served as a solid-state photodetector design template for the industry over the last several years. The MAPD-1 eventually evolved into the MAPD-2 and MAPD-3, providing better electrical efficiency and imaging capabilities than traditional integrated photo multiplier tubes (PMTs) in scanners.

For more information: www.frost.com, www.zecotek.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init